Additional file 1 of Urea cycle modulation by combined SGLT2 inhibitors and metformin

Additional file 1. Table S1. Quality control results for 620 metabolites in KORA-Fit. Table S2. Characteristics of the four mouse groups. Table S3. List of metabolites utilized in human serum and seven murine tissues. Table S4. Ten significant serum metabolites in COMBI vs. MET-T2D. Table S5. 82 significant plasma metabolites in COMBI vs. MET-db/db. Table S6. 52 significant liver metabolites in COMBI vs. MET-db/db. Table S7. 30 significant adrenal gland metabolites in COMBI vs. MET-db/db. Table S8. 12 significant adipose tissue metabolites in COMBI vs. MET-db/db. Table S9. Seven significant testis metabolites in COMBI vs. MET-db/db. Table S10. Seven significant lung metabolites in COMBI vs. MET-db/db. Table S11. Six significant cerebellum metabolites in COMBI vs. MET-db/db. Table S12. Threonine metabolism-associated liver transcripts in COMBI vs. MET-db/db. Table S13. Group comparisons between COMBI-T2D (N = 25) and MET-T2D (N = 138): effect sizes, confidence intervals, and post-hoc power. Table S14. Sensitivity analyses of the 10 metabolites in six models. Table S15. Correlation between HbA1C and 10 metabolites in T2D patients treated with COMBI or MET. Figure S1. Comparisons of the liver transcripts between COMBI-db/db and MET-db/db. Figure S2. Sensitivity analyses using propensity score matching (PSM).